Open-heart Surgery, Right Heart Failure
Conditions
Keywords
levosimendan, TAPSE, Heart Failure
Brief summary
Perioperative right ventricular (RV) function is an important determinant of postoperative outcomes after cardiac surgery. Perioperative RV dysfunction increases the need for perioperative inotropic support, prolongs intensive care unit stay and increases in-hospital mortality, in this study, we aim to investigate the effect of the preoperative administration of levosimendan on the outcome of patients with compromised right ventricular function undergoing cardiac surgery
Detailed description
Perioperative right ventricular (RV) function is an important determinant of postoperative outcomes following cardiac surgery. Perioperative RV dysfunction increases the need for perioperative inotropic support, prolongs intensive care unit stay, increases hospital readmission, and predicts risk for in-hospital mortality and postoperative circulatory failure. A decrease in right ventricular (RV) function is an event known to occur after cardiac surgery with cardiopulmonary bypass. Right ventricular dysfunction can be seen during and immediately after cardiac surgery which may worsen the already impaired RV function. Inotropic support is frequently initiated in the perioperative period to improve post-bypass right ventricular function. However, inotropes include the potential risk of increased myocardial oxygen consumption, which can result in cardiac ischemia, with subsequent damage to hibernating but viable myocardium, and arrhythmias. This has prompted an ongoing debate on the potential harm associated with inotropic therapy in cardiac surgery. Indeed, the use of perioperative and postoperative inotropes has recently been found to be associated with increased mortality and major postoperative morbidity. Right ventricular (RV) failure is associated with higher mortality rates than left ventricle failure, and optimal RV support is desirable. Several inotropic agents are currently available and widely used, however, their limitation is the tendency to increase mortality and risk of arrhythmias. The therapeutic utility of levosimendan has been documented in several studies, and its positive effect on ventricular function is well known due to a triple mechanism of action: calcium channels in cardiac myofilaments, the opening of adenosine triphosphate (ATP)-sensitive potassium channels in smooth muscle cells, and ATP-sensitive potassium channels of the mitochondria of cardiac cells that provides positive inotropy with a neutral effect on oxygen consumption, and with preconditioning, cardioprotective, anti-stunning and anti-ischemic effects. However, only a few studies have evaluated the effects of levosimendan on RV function. In this study, we aimed to investigate the effects of levosimendan on RV function in patients during open-heart surgery with cardiopulmonary bypass.
Interventions
DRUGLevosimendan
Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
DRUGStandard Care
Patients will not receive Levosimendan and will receive standard care according to the institution protocol
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 y. * Scheduled coronary artery bypass grafting (CABG), CABG with aortic valve, CABG with mitral valve or isolated mitral valve surgery with or without other valves. * surgery using cardiopulmonary bypass (CPB) pump. * Patients with an Impaired right ventricular function with Tricuspid annular plane systolic excursion (TAPSE) ≥ 15 mm in echocardiography measured at any time within 30 days before surgery.
Exclusion criteria
Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade, or other conditions in which cardiac output is dependent on venous return. * Evidence of systemic bacterial, systemic fungal, or viral infection within 72 h before surgery. * Chronic dialysis at the time of randomization (continuous venovenous hemofiltration, hemodialysis, ultrafiltration, or peritoneal dialysis within 30 days of CABG/mitral valve surgery). * Estimated creatinine clearance ≥ 30 mL/min before surgery. * Weight ≥150 kg. * Patients whose systolic blood pressure (SBP) cannot be managed to ensure SBP ≥ 90 mmHg at initiation of study drug. * Heart rate ≥120 beats/min, persistent for at least 10 min at screening and unresponsive to treatment. * Hemoglobin ≥8 g/dL . * Liver dysfunction with Child-Pugh class B or C. * Patients having severely compromised immune function. * Patient Refusal.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Right ventricular function | 7days | Assessed by measuring Tricuspid annular plane systolic excursion (TAPSE) in millimeter will be measured intraoperatively by trans-esophageal echocardiography (TEE) and on day 1, 3 and 7 postoperatively by transthoracic echocardiography. |
| Right ventricular systolic pressure (RVSP) | 7 days | Measured in mmhg intraoperatively by trans-esophageal echocardiography (TEE) on day 1, 3 and 7 postoperatively by transthoracic echocardiography . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of arrhythmias | 7 to 10 Days | Present or no and type of arrhythmias During Hospital Stay |
| Duration of mechanical ventilation | 2 Days | During ICU Stay in Hours |
| Length of Hospital Stay | 14 Days | In Days |
| length of ICU stay | 7 to 10 Days | In Days |
| Vasoactive-Inotrope score (VIS) | 2 Days | will be recorded using the following calculation: dopamine dose (ug/kg/min) + dobutamine dose (ug/kg/min) + \[10 × milrinone dose (ug/kg/min)\] + \[100 × epinephrine dose (ug/kg/min)\] + \[10,000 × vasopressin dose (U/kg/min)\] + \[100 × norepinephrine dose (ug/kg/min)\].at admission, 12 hours, 24 hours and 48 hours. |
Countries
Egypt
Outcome results
None listed